Oncolytics Biotech Inc ONCY

bioMedical Journal-the Lancet-2024 - Glioblastoma vaccines

[Noteable]

January/February 2024 - Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in adults. As supplements to standard of care (SOC), various immunotherapies improve the therapeutic effect in other cancers. Among them, tumour vaccines can serve as complementary monotherapy or boost the clinical efficacy with other immunotherapies, such as immune checkpoint blockade (ICB) and chimeric antigen receptor T cells (CAR-T) therapy.

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00529-7/fulltext

CALGARY, April 17, 2015 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY, a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN®, for the treatment of malignant glioma.  

https://www.prnewswire.com/news-releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-us-fda-for-malignant-gliomas-500265141.html

[inthno]

Yes the company did announce that on April 17th 2015 but they also announced this 2 months later. Oncolytics Biotech® Inc. Provides Update at AGM on Planned Registration Program for REOLYSIN® CALGARY, June 8, 2015 /PRNewswire/ – Oncolytics Biotech® Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics” or the “Company”) today provided an update on its planned registration program for

[Noteable]

The difference between then and now is that the FDA has since expanded the opportunity for biologics by enhancing the Accelerated Approval for biologics in rare/orphan diseases. What also changed towards the effective use of pelareorep in combination with immune checkpoint inhibitors (ICI) is the sequencing-in of pelareop before the administration of an ICI, so that pelareorep is able to "

[Noteable]

The Lancet reports that:  The rise of immuno-oncology in China: a challenge to western dominance? "There is also little doubt that biopharmaceuticals will become a core global industrial domain within China's Belt and Road Initiative." https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00026-8/fulltext